Covid-19 Medicine Market Size, Clinical Reviews by Expert and Healthcare Analysis 2021-2027 | Gilead Sciences Inc., IPCA, Zydus Cadila, I-Mab Biopharma, Airway Therapeutics

The Global demand for Covid-19 Medicine market in terms of revenue was worth of USD 1,790.2 Million in 2020 and is expected to reach USD 28.0 Million in 2027, growing at a CAGR of -51.4% from 2021 to 2027. From 2020 to 2021, the market is growing with 19.10% AGR. The global covid-19 medicine market is expected to grow at a significant growth rate due to the number of driving factors.

Scope of covid-19 medicine market:
Coronaviruses cause respiratory tract infections in humans that can only cause common cold and others that cause severe respiratory problem and ultimately death. As Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus i.e. SARS-CoV-2, which has spread rapidly throughout the world and in March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. This pandemic has severely weakened health systems & economic and social progress globally. While countries, have taken strong measures to cover the spread of COVID-19 through better diagnostics and treatment, the coronavirus medicine may provide an effective solution by enhancing immunity and controlling the disease spread.

Get Sample of This Report:@https://brandessenceresearch.com/requestSample/PostId/1474?utm_source=opr&utm_medium=Djay

Some major key players for COVID-19 Medicine market are,
Currently, many companies are heavily investing on produce highly effective drugs and gain approvals for the drugs from government organization.

Gilead Sciences, Inc.
IPCA
Zydus Cadila
I-Mab Biopharma
Airway Therapeutics
Tiziana Life Sciences
OyaGen
BeyondSpring
Algernon Pharmaceuticals
Others

The global COVID-19 Medicine market research reports segments as follows:
Global COVID-19 Medicine Market: By Drug Type
Remdesivir
Hydroxychloroquine, Chloroquine
Others (Other Anti Viral, Multivitamins, Corticosteroids and Others)
Global COVID-19 Medicine Market: By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others (ACC)

The regions covered in global Covid-19 medicine market are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global amyotrophic Covid-19 medicine market is sub divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.

Market Trends of COVID-19 Medicine Market
In recent years, scientists and leading organizations are developing various drugs by using a wide range of techniques some of which are never been approved for medical purposes before and some of which are already well established. While manufacturing, drugs manufacturers are focused on the speedy recovery of patients. To overcome the effects or decrease the risk of coronavirus the number of drug companies are ready to enter the market. Additionally, the increasing number of coronavirus patients is the major factor as well as the concern globally. Coronavirus is adversely impacted all economies worldwide. Following are some drugs that are approved by the government for coronavirus cases in the emergency use:

A) Remdesivir:

On 22nd October, 2020; The U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. The approval of Veklury was supported by the agency’s analysis of data from three randomized, controlled clinical trials that included patients hospitalized with mild-to-severe COVID-19. The FDA has granted an emergency use authorization for the rheumatoid arthritis drug baricitinib to treat COVID-19 in some cases. Baricitinib is a pill that seems to work against COVID-19 by reducing inflammation and having antiviral activity. According to FDA, baricitinib may be used in combination with remdesivir in people who are hospitalized with COVID-19 who are on mechanical ventilators or need supplemental oxygen.

B) Hydroxychloroquine/Chloroquine:

Chloroquine and Hydroxychloroquine increase the endosomal pH, inhibiting combination of severe acute respiratory syndrome coronavirus 2 and the host cell membranes. Chloroquine prevents glycosylation of the cellular angiotensin-converting enzyme 2 receptor, which may interfere with the binding of severe acute respiratory syndrome-associated coronavirus to the cell receptor. The US Food and Drug Administration approved limited emergency use for chloroquine and hydroxychloroquine as a treatment for COVID-19. Chloroquine is being tested in various clinical trials conducted by government agencies and academic institutions. Other antivirals drugs are also planned to be fast-tracked for testing for Coronavirus. Hydroxychloroquine and chloroquine have antiviral properties against SARS-CoV-2, the virus that causes COVID-19.

C) Favilavir:

On February 21st, 2020; Zhejiang Hisun Pharmaceutical’s anti-viral drug Favilavir (Favipiravir) has been approved as an investigational therapy to treat the coronavirus, reported by local media. According to media reports, Favilavir has been approved by China as the first antiviral drug against coronavirus. The anti-viral drug Favilavir has been approved by the National Medical Product Treatment Administration of China for the treatment of coronavirus covid-1 treat. Favilavir has been approved for marketing in the treatment of influenza and is one of three drugs that have shown efficacy against coronavirus in human trials. For example, Favipiravir sells under the brand name Avigan and is an approved drug for the treatment of influenza. The drug will be sold under the Brandon Faviton brand and will be available in 200 mg and 400 mg tablets. Pune-based pharmaceutical marketing company Britton Pharmaceuticals is all set to export the anti-viral drug Favpipirvir to one of the countries, awaiting the approval of the Indian Drug Controller to bring the drug to India.

Full Research Report:@https://brandessenceresearch.com/healthcare/covid-medicine-market

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com
Website: https://brandessenceresearch.com/

About Us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

This release was published on openPR.